The weight-loss market is heating up as a number of companies are looking for a way to upend the dominance of market leaders Novo Nordisk , Novo, and a smaller biotech prove that an oral option could be as effective as injectables, but Wall Street is waiting to see whether or not patients will prefer a daily pill to a weekly or monthly injectable.
The frontrunner is Lilly's orforglipron, which showed up to 14.7% weight loss in Phase 2 trials at 36 weeks. It has set the bar for other contenders and gives investors confidence in the current injectable market leader's ability to capture market share. Closeup of the big three injectable prescription weight loss medicines: Ozempic, Victoza, and Wegovy.
Dr. Michael Weintraub, an endocrinologist and obesity medicine specialist at NYU Langone Health in New York City, says that competition is necessary because all patients are not the same.
Sverige Senaste nytt, Sverige Rubriker
Similar News:Du kan också läsa nyheter som liknar den här som vi har samlat in från andra nyhetskällor.
Källa: YahooFinanceCA - 🏆 47. / 63 Läs mer »
Källa: YahooFinanceCA - 🏆 47. / 63 Läs mer »